Literature DB >> 33860919

Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

Joerg Putzke1, Scott Haughie2, Kelly H Zou3, Gopinath M Ranganna4.   

Abstract

Entities:  

Year:  2021        PMID： 33860919     DOI： 10.1007/s40259-021-00476-9

Source DB:  PubMed          Journal:  BioDrugs        ISSN： 1173-8804            Impact factor:   5.807


× No keyword cloud information.
  3 in total

1.  Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.

Authors:  Ana Szarfman; Stella G Machado; Robert T O'Neill
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Author's Reply to Joerg Putzke et al. Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database".

Authors:  Jingjing Qian; Cong Bang Truong; Kaniz Afroz Tanni
Journal:  BioDrugs       Date:  2021-04-16       Impact factor: 5.807

Review 3.  Data mining of the public version of the FDA Adverse Event Reporting System.

Authors:  Toshiyuki Sakaeda; Akiko Tamon; Kaori Kadoyama; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-04-25       Impact factor: 3.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.